Cure8 research brief
The abstract suggests a new AhR-targeting drug candidate, EQ504, may more strongly drive epithelial repair and barrier-related gene changes in lab models than an existing clinical AhR agonist, which could be relevant to therapies aimed at mucosal healing in ulcerative colitis.
Researchers, translational scientists, clinicians focused on IBD and mucosal healing
The study is preclinical and used cell-based assays (HepG2 EROD assay and T84 intestinal epithelial scratch-wound assays) to compare EQ504 with obefazimod, a clinically studied AhR agonist.
EQ504 produced stronger AhR activation in the reporter assay, faster wound closure in epithelial scratch tests, increased expression of the IL-22 receptor subunit (IL22RA), and decreased expression of the pore-forming tight junction protein claudin-2 (CLDN2) at matched concentrations.
The authors interpret these findings as evidence of superior epithelial-repair and barrier-stabilizing activity for EQ504 versus obefazimod. The reported work supports continued development of EQ504 for inflammatory mucosal diseases, but the results are from in vitro models rather than human trials.
Ongoing studies noted in the abstract include transepithelial electrical resistance measurements and human intestinal organoid models, which would provide more physiologic data but are not reported here.
Results are from in vitro cell assays reported in an abstract. The work is preclinical and does not provide clinical safety or efficacy data. The abstract notes ongoing additional laboratory studies but no human data are reported.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This study reports real-world data on mirikizumab in adults with ulcerative colitis, focusing on clinical and endoscopic remission and inflammatory markers — outcomes patients and clinicians use to judge treatment...
Early clinical data suggest PALI-2108 may affect both inflammation and fibrosis in Crohn’s disease and shows biomarker changes (like fecal calprotectin) that could matter to people monitoring disease activity.
This trial tests palmitoylethanolamide (PEA), a commercially available supplement with anti-inflammatory actions, as an add-on treatment for mild-to-moderate ulcerative colitis.
